Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells 10,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $39.10, for a total value of $391,000.00. Following the sale, the senior vice president now owns 151,911 shares of the company’s stock, valued at approximately $5,939,720.10. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO traded up $0.66 during mid-day trading on Tuesday, hitting $39.77. The stock had a trading volume of 615,672 shares, compared to its average volume of 1,280,727. Halozyme Therapeutics, Inc. has a 52 week low of $29.85 and a 52 week high of $59.46. The company has a current ratio of 6.58, a quick ratio of 5.44 and a debt-to-equity ratio of 9.91. The stock has a market capitalization of $5.25 billion, a price-to-earnings ratio of 22.87, a P/E/G ratio of 0.61 and a beta of 1.24. The company has a 50 day simple moving average of $41.75 and a 200-day simple moving average of $37.63.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.09. Halozyme Therapeutics had a return on equity of 254.75% and a net margin of 30.21%. The business had revenue of $221.04 million during the quarter, compared to analyst estimates of $201.91 million. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 2.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Morgan Stanley lifted their price target on shares of Halozyme Therapeutics from $60.00 to $61.00 and gave the stock an “overweight” rating in a research note on Thursday, August 10th. The Goldman Sachs Group cut shares of Halozyme Therapeutics from a “buy” rating to a “neutral” rating and increased their price target for the stock from $43.00 to $45.00 in a research report on Monday, July 24th. Piper Sandler boosted their price objective on Halozyme Therapeutics from $46.00 to $48.00 in a report on Wednesday, August 9th. TheStreet upgraded Halozyme Therapeutics from a “c+” rating to a “b” rating in a research note on Tuesday, August 8th. Finally, StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, August 16th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $54.27.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors have recently made changes to their positions in HALO. Portside Wealth Group LLC acquired a new stake in Halozyme Therapeutics during the second quarter valued at approximately $4,933,000. Alberta Investment Management Corp acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth $558,000. Virginia Retirement Systems ET AL purchased a new stake in shares of Halozyme Therapeutics during the second quarter valued at $379,000. Teachers Retirement System of The State of Kentucky boosted its position in shares of Halozyme Therapeutics by 10.3% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 24,374 shares of the biopharmaceutical company’s stock valued at $879,000 after purchasing an additional 2,270 shares during the period. Finally, Coastal Bridge Advisors LLC purchased a new position in Halozyme Therapeutics in the 2nd quarter worth about $216,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.